Global Insulin Glargine Market – Industry Trends and Forecast to 2028

  • Healthcare
  • Upcoming Report
  • Jan 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Insulin Glargine Market, By Type (Single Dose Vial and Pre-Filled Syringe), Application (Treat Type 2 Diabetes and Treat Type 1 Diabetes), Distribution Channel (Hospital Pharmacy, Online Sales, Retail Pharmacy and Other Distribution Channels), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Insulin Glargine Market Market Analysis and Insights of Global Insulin Glargine Market

Global insulin glargine market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 7,164.68 million by 2028 growing at a CAGR of 10.89% in the above-mentioned forecast period. The growing awareness amongst the physicians and patients regarding the benefits associated with the usage of insulin glargine has been directly impacting the growth of insulin glargine market.

Insulin glargine is long-acting basal insulin that is mainly given to diabetes patients daily to control blood sugar levels. Insulin glargine consists of microcrystals which slowly releases insulin and provides a long duration of action. It is man-made insulin which is normally produced by the body and helps in case of diabetes to remove sugar from the blood. It is also used to reduce the sugar-producing ability of the liver.

Growth in the diagnosis of diabetes and an increase in demand for insulin for diabetes patients is the main driving factor for the insulin glargine market. Increasing remunerate policies, awareness of health, and advancement in technology of insulin delivery devices is an opportunity for the insulin glargine market.

Higher cost of the products is the main challenge for the insulin glargine market. However, strict policies and regulations for the product approval and availability of substitutes is the main restraint in the growth of insulin glargine market during the forecast period of 2021-2028.

This insulin glargine market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Data Bridge Market Research insulin glargine market contact us for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Insulin Glargine Market Scope and Market Size

Insulin glargine market is segmented on the basis of type, application and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • Based on type, the insulin glargine market is segmented into single dose vial and pre-filled syringe.
  • Insulin glargine market has also been segmented based on application into treat type 2 diabetes and treat type 1 diabetes.
  • Based on distribution channel, the insulin glargine market is segmented into hospital pharmacy, online sales, retail pharmacy and other distribution channels.

Insulin Glargine Market Country Level Analysis

Insulin glargine market is analysed and market size insights and trends are provided by country, type and application and distribution channel as referenced above.

The countries covered in the insulin glargine market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the insulin glargine market due to increase in diabetes patients in the region and increasing medical expenditure. Health awareness among the people is another reason for growth of market, while Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2021 to 2028 due to increase in healthcare expenses and development of health and medical infrastructure.

The country section of the insulin glargine market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Insulin glargine market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for insulin glargine market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the insulin glargine market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Insulin Glargine Market Share Analysis

Insulin glargine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to insulin glargine market.

The major players covered in the insulin glargine market report are Biocon, Sanofi-Aventis, Novo Nordisk A/S, Gan & Lee Pharmaceuticals, Eli Lilly and Company, LGM Pharma, Trumac Healthcare, ADOCIA, Lupin Ltd, WOCKHARDT, Cipla Inc., Biocon Biologics, Pfizer Inc., Biogenomics Limited., Loka BioSciences, Amigoz Lifesciences, Endocrine Technologies, Inc., Spectrum Chemical Mfg. Corp., Sekisui Diagnostics, LLC, Alfa Chemical Corp., Accurate Chemical & Scientific Corporation among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

In September 2020, Biocon Biologics introduced Semglee (insulin glargine injection) in the U.S. The drug helps control high blood sugar in adults and children with type 1 and type 2 diabetes. Semglee, who received final approval from the U.S. Food and Drug Administration (FDA) in June, has the same amino acid as Sanofi's Lantus. The drug is already in use in 45 countries but entry into the U.S. is significant because the cost of insulin has shot so high that one in four people with diabetes is now skipping or skipping life-saving doses. With this launch, the company has enhanced its offering in the market.

Customization Available : Global Insulin Glargine Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Frequently Asked Questions